New advances in the clinical management of RAS and BRAF mutant colorectal cancer patients.
Jose Carlos RuffinelliCristina Santos VivasRebeca Sanz-PamplonaVictor MorenoPublished in: Expert review of gastroenterology & hepatology (2020)
With great advances in the knowledge of molecular basis of RAS and BRAF mutant colorectal cancer in conjunction with biotechnology development and the constant effort for improvement, in the near future many new therapeutic options would be available for the management of this group of patient with dismal prognosis.